Axonia Medical is developing proprietary tissue-engineered nerve grafts (TENGs) that recapitulate nervous system anatomy to bridge lost nervous tissue and jump-start regenerative mechanisms. The company’s platform targets functional repair of peripheral and central nervous system injuries, including peripheral nerve injury, spinal cord injury, traumatic brain injury and stroke. Axonia’s lead program focuses on peripheral nerve injury after traumatic injury and tumor resection, areas with significant unmet medical need due to limited existing treatment options. The technology leverages discoveries by scientific founder Dr. Douglas H. Smith at the University of Pennsylvania and the company emphasizes an established intellectual property position. Management plans to use the seed funding to accelerate development, demonstrate efficacy in large animal models and position products for human clinical testing. Axonia is privately held and located in Kalamazoo, Michigan.

Total raised

$2M

Funding rounds

1

Latest round

Seed

Latest activity

May 2012